INT131692

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 9
Total Number 9
Disease Relevance 4.69
Pain Relevance 4.82

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (App) Golgi apparatus (App) plasma membrane (App)
extracellular matrix organization (App) DNA binding (App) cytoplasm (App)
Anatomy Link Frequency
plaque 2
App (Mus musculus)
Pain Link Frequency Relevance Heat
Abeta 48 100.00 Very High Very High Very High
tetrodotoxin 6 99.48 Very High Very High Very High
cINOD 37 99.34 Very High Very High Very High
cytokine 42 94.84 High High
Inflammatory response 12 94.32 High High
fibrosis 2 92.00 High High
Inflammation 67 77.12 Quite High
Inflammatory mediators 7 56.32 Quite High
agonist 22 50.00 Quite Low
Inflammatory marker 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Alzheimer's Dementia 32 100.00 Very High Very High Very High
Targeted Disruption 25 100.00 Very High Very High Very High
Immunization 15 100.00 Very High Very High Very High
INFLAMMATION 104 97.52 Very High Very High Very High
Disease 226 97.16 Very High Very High Very High
Fibrosis 2 92.00 High High
Drug Induced Neurotoxicity 2 75.44 Quite High
Body Weight 2 73.20 Quite High
Amyloid Plaque 7 70.00 Quite High
Cognitive Disorder 16 68.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Here we find that (R)-flurbiprofen, the R-enantiomer of the racemate NSAID flurbiprofen, can significantly reduce Abeta secretion, but at the same time, increases the level of intracellular Abeta.
Negative_regulation (reduce) of Localization (secretion) of Abeta associated with cinod and abeta
1) Confidence 0.53 Published 2009 Journal J. Neurochem. Section Abstract Doc Link 19659691 Disease Relevance 0.77 Pain Relevance 1.03
The APP/PS1 mouse model used in our study possesses concurrent mutated forms of APP and Presenilin 1 (PS1), both identified separately in human Alzheimer diseases [1].
Negative_regulation (possesses) of Localization (forms) of APP associated with disease
2) Confidence 0.42 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2696039 Disease Relevance 0.49 Pain Relevance 0.05
We also show that (R)-flurbiprofen can interfere with the interaction between RXRalpha and 9-cis-retinoid acid, and that 9-cis-retinoid acid decreases (R)-flurbiprofen's reduction of Abeta secretion.
Negative_regulation (reduction) of Localization (secretion) of Abeta associated with abeta
3) Confidence 0.39 Published 2009 Journal J. Neurochem. Section Abstract Doc Link 19659691 Disease Relevance 0.51 Pain Relevance 0.96
peptide production, and inhibit soluble APP secretion (Blasko et al 1999).
Negative_regulation (inhibit) of Localization (secretion) of APP
4) Confidence 0.38 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2626915 Disease Relevance 0.55 Pain Relevance 0.28
immunization of APP transgenic mice reduced plaque burden in mice stimulated
Negative_regulation (reduced) of Localization (immunization) of APP in plaque associated with targeted disruption and immunization
5) Confidence 0.37 Published 2008 Journal PPAR Research Section Body Doc Link PMC2442897 Disease Relevance 1.44 Pain Relevance 0
Inhibition of cathepsin B (catB) activity with CA074Me or attenuation of catB expression through small interfering RNA produced decreases in Abeta release, similar to levels produced with suppression of beta-site APP-cleaving enzyme 1 (BACE1) expression.
Negative_regulation (decreases) of Localization (release) of Abeta associated with abeta
6) Confidence 0.14 Published 2009 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 19064719 Disease Relevance 0.21 Pain Relevance 0.48
These comparisons demonstrated no additivity between decreases in Abeta release produced by TTX and CA074Me.
Negative_regulation (decreases) of Localization (release) of Abeta associated with tetrodotoxin and abeta
7) Confidence 0.11 Published 2009 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 19064719 Disease Relevance 0.23 Pain Relevance 0.61
Surprisingly, we found that two ROCK inhibitors reduced total Abeta secretion in a dose-dependent manner but showed no selectivity for Abeta42.
Negative_regulation (reduced) of Localization (secretion) of Abeta associated with abeta
8) Confidence 0.07 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 16300630 Disease Relevance 0.22 Pain Relevance 0.72
Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.
Negative_regulation (Inhibitors) of Localization (secretion) of Abeta associated with alzheimer's dementia and abeta
9) Confidence 0.05 Published 2006 Journal J. Neurochem. Section Title Doc Link 16300630 Disease Relevance 0.25 Pain Relevance 0.68

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox